Contact us
Detecting Hepatitis
Viral hepatitis is most commonly caused by the hepatitis A, B, and C viruses, but it can also be caused by infection with hepatitis E virus. The severity of disease varies depending on the causative virus; the first step in diagnosing hepatitis infections is to identify the type of virus and when it was contracted using highly sensitive immunoassays against virus specific antibodies.
Early and effective detection of hepatitis B or C infections is critical for initiating early treatment which may yield a better prognosis by enabling medical treatment to be directed accordingly to inhibit disease progression.
OnSite® HCV Ab Plus Rapid Test (Strip)
The OnSite® HCV Ab Plus Rapid Test is a double antigen lateral flow chromatographic immunoassay for the qualitative detection of anti-hepatitis C virus antibodies (IgG, IgM, IgA) in human serum or plasma.
OnSite® HCV Ab Plus Combo Rapid Test
The OnSite® HCV Ab Plus Combo Rapid Test is a double antigen lateral flow chromatographic immunoassay for the qualitative detection of anti-hepatitis C virus antibodies (IgG, IgM, IgA) in human serum, plasma, or whole blood.
OnSite® HBsAg Rapid Test (Strip)
The OnSite® HBsAg Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of Hepatitis B surface antigen (HBsAg) in human serum or plasma at a level equal to or higher than 1 ng/mL.
OnSite® HBsAg Combo Rapid Test
The OnSite® HBsAg Combo Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of hepatitis B surface antigen
(HBsAg) in human serum, plasma or whole blood.
OnSite® HBsAg/HCV Ab Rapid Test
The OnSite® HBsAg/HCV Ab Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibodies (IgG, IgM, IgA) in human serum, plasma or whole blood.
OnSite® HIV/Syphilis/HBV/HCV Panel Rapid Test
The OnSite® HIV/Syphilis/HBV/HCV Panel Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and HCV in human serum, plasma, or whole blood.
OnSite® HBV-5 Rapid Test
The OnSite® HBV-5 Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B e-antigen (HBeAg), hepatitis B e-antibody (HBeAb), and hepatitis B core antibody (HBcAb) in human serum or plasma.
HBsAg ELISA
The RecombiLISA HBsAg ELISA is a solid-phase enzyme-linked immunosorbent assay based on the principle of the antibody sandwich technique.
HBcAb ELISA
The RecombiLISA HBcAb ELISA is a solid-phase enzyme-linked competitive immunosorbent assay for the qualitative detection of antibodies (IgG and IgM) anti-hepatitis B virus (HBV) core antigen in human serum or plasma.
HCV IgG ELISA
The RecombiLISA HCV IgG ELISA is a solid phase enzyme-linked immunosorbent assay for the qualitative detection of IgG to hepatitis C virus (HCV) in human serum or plasma.
A solution for population screening to prevent transfusion-related transmission.
HCV IgG ELISA
The RecombiLISA HCV Ab ELISA is a solid phase enzyme-linked immunosorbent assay for the qualitative detection of antibodies (both IgG and IgM) to Hepatitis C virus (HCV) in human serum or plasma.
An effective solution for population screening to identify infected carriers and screening of donors and blood supplies to prevent transfusion-related transmission.
Why OnSite®?
Viral hepatitis is most commonly caused by the hepatitis A, B, and C viruses, but it can also be caused by infection with hepatitis E virus. The severity of disease varies depending on the causative virus; the first step in diagnosing hepatitis infections is to identify the type of virus and when it was contracted using highly sensitive immunoassays against virus specific antibodies.
Early and effective detection of hepatitis B or C infections is critical for initiating early treatment which may yield a better prognosis by enabling medical treatment to be directed accordingly to inhibit disease progression.
Get in touch
If you have any questions, comments, or collaboration inquiries, you are very welcome to reach out.
Please fill in the form and we will get back to you as soon as possible.